Primary Human Brain Tumor Cells
Primary Human Brain Tumor Cells - Related Videos
03:45
Tumor Treating Fields Application in Human Brain Tumor Models: A Non-invasive Technique to Deliver Alternating Electric Fields to Human Brain for Treating Brain Tumor
0 Views •
2023
This video demonstrates the application of Tumor Treating Fields or TTFields in human brain tumor models. This non-invasive technique delivers low-intensity alternating electric fields directly to the brain, resulting in inhibition of cell division and subsequent apoptosis.
04:50
Delivering Effector T Lymphocytes into Mice Carrying Human Brain Tumors
0 Views •
2025
This video demonstrates a stereotaxic injection technique for administering human effector T lymphocytes into a murine model carrying a human brain tumor. Upon positioning a tumor-bearing anesthetized mouse on a stereotactic frame and creating a burr hole at the injection location on the skull, effector T lymphocytes are injected at the tumor site.
Isolation of Immune Cells from Primary Tumors
0 Views •
Cited by 18 •
2012
In this report, we describe a protocol for isolating highly purified populations of leukocytes that infiltrate tumors. This protocol is adapted from the Miltenyi Biotech protocol to enhance yield and purity for isolating cells from complex tumor tissue.
09:28
Isolation of Primary Human Colon Tumor Cells from Surgical Tissues and Culturing Them Directly on Soft Elastic Substrates for Traction Cytometry
0 Views •
Cited by 11 •
2015
A protocol is described to extract primary human cells from surgical colon tumor and normal tissues. The isolated cells are then cultured on soft elastic substrates (polyacrylamide hydrogels) functionalized by an extracellular matrix protein, and embedded with fluorescent microbeads. Traction cytometry is performed to assess cellular contractile stresses.
08:14
Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting
0 Views •
Cited by 21 •
2012
The identification of brain tumor initiating cells (BTICs), the rare cells within a heterogeneous tumor possessing stem cell properties, provides new insights into human brain tumor pathogenesis. We have refined specific culture conditions to enrich for BTICs, and we routinely use flow cytometry to further enrich these populations. Self-renewal assays and transcript analysis by single cell RT-PCR can subsequently be performed on these isolated cells.
FAQs
Because they come from surgical specimens, these cultures can retain features of the original malignancy that may be altered during long-term maintenance of established cell lines. That distinction makes them useful for examining patient-associated tumor behavior, including proliferation, invasion, and treatment response. They therefore provide a complementary model when researchers want laboratory findings to remain closely connected to human disease.
Tracking these features shows whether the cultured cells continue to display properties associated with the original tumor. Growth measurements indicate proliferative behavior, morphology records visible cellular changes, and molecular characterization examines tumor-associated features at a biological level. Together, these observations help researchers judge how consistently the culture represents the malignancy during experiments and treatment testing.
These cultures support investigation of several clinically relevant behaviors rather than cell growth alone. Researchers can examine how tumor cells proliferate, invade surrounding environments, respond to candidate treatments, and interact with components of the tumor microenvironment. Studying these processes in patient-derived material can connect cellular observations with disease mechanisms that matter in medicine and cancer research.
The workflow begins with a surgical brain tumor specimen, which is processed to dissociate the tissue into viable cells. Those cells are then placed under defined culture conditions and maintained while their growth, morphology, and molecular characteristics are monitored. This sequence links specimen collection to quality assessment, allowing researchers to establish cultures suitable for subsequent biological or treatment-focused experiments.
Candidate therapies can be tested by observing how patient-derived tumor cells respond under laboratory conditions. Treatment response is assessed alongside cellular behavior, such as proliferation or invasion, so investigators can compare therapeutic effects with relevant tumor properties. This approach supports early evaluation of potential treatments and may help identify differences in response associated with patient-specific disease mechanisms.
Their patient-linked origin provides a foundation for connecting laboratory experiments with clinical questions. Findings from these cultures can support translational studies of tumor biology and candidate treatments while preserving a direct relationship to an individual malignancy. In that context, the cells may contribute to personalized treatment strategies by helping investigators examine disease mechanisms and therapeutic responses in patient-specific material.